Abstract
N95 respirators reduce risk of catching COVID-19 from an infected person both at near-field (e.g. < 6 feet) and far-field (e.g. > 6 feet). Air filtration is usually not effective at near-field, but emulating the far-field equivalent of N95 requires 95% reduction of particles (20x) from airborne particulate sources. A wide range of air change per hour (ACH) recommendations for air filtration exist ranging from 2 to 12 ACH (CDC, CDPH, etc.). Instead of inert airborne contaminant (e.g. salt water) which can be disruptive in occupied rooms, we describe a simpler procedure using an optical particle counter to track the decay of ambient aerosols (0.3□μm diameter) and measure ACH from exponential decay coefficients in a room and a whole house. Surface deposition in an unventilated room without ventilation or filtration was measured to be 0.6 ACH using ambient aerosols. ACH was also measured to be 3 to 17 using low-noise generating HEPA purifiers ($299-$999, reported CADR 114 to 1360 cfm) and Do-It-Yourself (DIY) air purifiers ($55-$160, 1”-5”, MERV 13-16, 1-filter and 4-filter Corsi-Rosenthal boxes). Using ACH and volume of room/house, estimated CADR per dollar varied 4x from below 80 cfm / $100 for tested HEPA purifiers at their highest speed (for maximum CADR) up to above 350 cfm / $100 run with tested DIY air purifiers running on their lowest speed (for reduced noise generation). Differences in CADR were observed in room versus house, and purifiers with higher airspeed had higher than expected CADR, possibly reflecting better mixing. Using 0.6 ACH as baseline for unventilated rooms, at least 12 ACH is required for far-field protection equivalent to N95 respirators (95%), and this ACH can be achieved using either HEPA or DIY air filtration in a room or building and verified with ambient aerosols.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
sri{at}patientknowhow.com, www.patientknowhow.com
Updated discussion section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
